FOR CAMBRIDGE-BASED Biogen, it’s been the best of times and the worst of times. The biotech powerhouse saw its Alzheimer’s drug Aduhelm approved in June by the Food and Drug Administration. The first new Alzheimer’s therapy in nearly 20 years, the drug looked poised to become a blockbuster treatment that would reap billions in sales […]
Biogen
Posted inHealth Care
FDA’s controversial approval of Alzheimer’s drug draws calls for reform
WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the state’s leading provider network. On Thursday, Blue Cross Blue Shield of Massachusetts, the state’s largest private insurer, said it won’t cover the drug developed by […]
Posted inHealth Care
Insurers put squeeze on Biogen Alzheimer’s drug
CALL IT THE first big shot across Biogen’s bow in what may become a multi-billion-dollar war in which the hopes of millions for a way to hold back the ravages of Alzheimer’s disease are colliding with the uncertain benefits of a new drug and the explosion of already sky-high health care costs its widespread use […]